Paul K. Audhya - Net Worth and Insider Trading

Paul K. Audhya Net Worth

The estimated net worth of Paul K. Audhya is at least $1 Million dollars as of 2025-07-02. Paul K. Audhya is the CHIEF MEDICAL OFFICER of KalVista Pharmaceuticals Inc and owns about 113,026 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $1 Million. Details can be seen in Paul K. Audhya's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Paul K. Audhya has not made any transactions after 2025-05-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Paul K. Audhya

Paul K. Audhya Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paul K. Audhya owns 1 companies in total, including KalVista Pharmaceuticals Inc (KALV) .

Click here to see the complete history of Paul K. Audhya’s form 4 insider trades.

Insider Ownership Summary of Paul K. Audhya

Ticker	Company	Transaction Date	Type of Owner
KALV	KalVista Pharmaceuticals Inc	2025-05-23	Chief Medical Officer

Paul K. Audhya Latest Holdings Summary

Paul K. Audhya currently owns a total of 1 stock. Paul K. Audhya owns 113,026 shares of KalVista Pharmaceuticals Inc (KALV) as of May 23, 2025, with a value of $1 Million.

Latest Holdings of Paul K. Audhya

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
KALV	KalVista Pharmaceuticals Inc	2025-05-23	113,026	11.60	1,311,102

Holding Weightings of Paul K. Audhya

Paul K. Audhya Form 4 Trading Tracker

According to the SEC Form 4 filings, Paul K. Audhya has made a total of 17 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 0 buys and 17 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the sale of 2,146 shares on May 23, 2025, which brought Paul K. Audhya around $24,271.

Insider Trading History of Paul K. Audhya

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Paul K. Audhya Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Paul K. Audhya Ownership Network

Ownership Network List of Paul K. Audhya

No Data

Ownership Network Relation of Paul K. Audhya

Paul K. Audhya Owned Company Details

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Paul K. Audhya is the Chief Medical Officer of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Development Officer Christopher Yea , and 10 percent owner Venrock Healthcare Capital Partners Iii, L.p. .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Paul K. Audhya made 11 insider transaction in KalVista Pharmaceuticals Inc (KALV) with a net sale of 60,972. Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net sale of 169,424 shares made by Benjamin L Palleiko , a net purchase of 1,093,212 shares made by Venrock Healthcare Capital Partners Iii, L.p. , and a net sale of 93,084 shares made by Christopher Yea .

In summary, during the past 3 months, insiders sold 35,430 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 25,000 shares, with a net sale of 10,430 shares. During the past 18 months, 521,271 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,093,212 shares were bought by its insiders, resulting in a net purchase of 571,941 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

Paul K. Audhya Mailing Address

Above is the net worth, insider trading, and ownership report for Paul K. Audhya. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Paul K. Audhya's mailing address is: Cambridge Ma 02142.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.